CALCA and migraine disorder: Long-term studies through 2024 continue to support ongoing safety and efficacy for all four monoclonal antibodies, building evidence for earlier access to CGRP treatment as they increase quality of life and reduce monthly migraine days while being better tolerated than non-specific migraine preventative therapies (74).